stockrowHeron Therapeutics, Inc.
HRTX Healthcare Biotechnology
Heron Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $154.9 million, up 7.36% from fiscal 2024.
- Revenue
- +1.25%
- EPS
- −93.6%
- Free cash flow
- +78.8%
- Total debt
- −18.5%
Quarter to June 2026, against a year earlier
Follow HRTX
Alert me
Heron Therapeutics, Inc. (HRTX) EV/Sales
As of 6 November 2026, Heron Therapeutics, Inc. (HRTX) trades at a EV/Sales of 1.0×. Over the past ten years it has ranged from 0.0× (March 2017) to 159× (April 2017); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | (17.00%) |
| FY2024 | 2.4× | (13.37%) |
| FY2023 | 2.8× | (8.70%) |
| FY2022 | 3.1× | (70.37%) |
| FY2021 | 10.3× | (47.09%) |
| FY2020 | 19.5× | 84.39% |
| FY2019 | 10.6× | (48.53%) |
| FY2018 | 20.5× | (25.86%) |
| FY2017 | 27.7× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.2× | (27.07%) |
| Mar 2026 | 1.6× | (17.78%) |
| Dec 2025 | 2.0× | 4.12% |
| Sep 2025 | 1.9× | (36.36%) |
| 34 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| BOLD Boundless Bio, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| HRTX Heron Therapeutics, Inc. | 1.0× |
| VRCA Verrica Pharmaceuticals Inc. compare | 2.3× |
| RNXT RenovoRx, Inc. compare | 17.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)